Aurora-A and hBora join the game of Polo.
Overactivation of both Polo-like kinase-1 (Plk1) and Aurora-A is linked to cancer development, and small-molecule inhibitors that target these kinases are currently tested as anticancer drugs. Here, we discuss recent advances in the understanding of the functional crosstalk between Plk1 and Aurora-A before and during mitosis. Several recent findings have led to a better appreciation of how the activities of these distinct mitotic kinases are intertwined. Such insight is important for the expected utility of small-molecule inhibitors targeting Plk1 or Aurora-A, and it might help us to improve their application.
Macurek
Libor
L
Department of Medical Oncology and Cancer Genomics Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Lindqvist
Arne
A
Medema
René H
RH
D000818:Animals; D064127:Aurora Kinases; D018797:Cell Cycle Proteins / Q000378:metabolism* / Q000502:physiology*; D004789:Enzyme Activation / Q000502:physiology; D016195:G2 Phase / Q000502:physiology; D006801:Humans; D008938:Mitosis / Q000502:physiology; D008954:Models, Biological; D011499:Protein Processing, Post-Translational / Q000502:physiology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism* / Q000502:physiology*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D000097869:Polo-Like Kinase 1
D064127:Aurora Kinases; D018797:Cell Cycle Proteins; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000097869:Polo-Like Kinase 1; C528235:bora protein, human